

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-11. (canceled)

12. (previously presented) A method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 activity to a patient in need thereof.

13. (withdrawn) The method according to claim 12, wherein the inhibitor is a nucleic acid.

14. (withdrawn) method according to claim 12, wherein the inhibitor is a small molecule (NCE).

15. (previously presented) The method according to claim 12, wherein the inhibitor is an antibody or a functionally active antibody fragment or derivative.

16. (currently amended) The method according to claim 15, wherein the antibody or antibody fragment is ~~monoclonal, polyclonal, chimeric, humanized or bispecific~~.

17. (withdrawn) The method according to claim 15 wherein the antibody fragment is a Fab, Fab', F(ab').sub.2, scFv or epitope binding fragment.

18. (previously presented) The method according to claim 15 wherein the antibody or antibody fragment is conjugated to one or more effector molecule(s).

19. (previously presented) The method according to claim 15 wherein the antibody or antibody fragment binds to CSF-1.

20. (withdrawn) The method according to claim 15 wherein the antibody or antibody fragment binds to CSF-1R.

21. (previously presented) The method according to claim 12 wherein the inflammatory bowel disease is Crohn's disease.

22. (withdrawn) The method according to claim 12 wherein the inflammatory bowel disease is ulcerative colitis.

23. (previously presented) The method according to claim 12 wherein the inhibitor of CSF-1 activity is administered in combination with one or more other therapeutically active compounds.

24. (previously presented) The method according to claim 23 wherein the other therapeutically active compound is another anti-IBD therapeutic agent.

25. (withdrawn) The method according to claim 23 wherein the other therapeutically active compound is an anti-cancer therapeutic agent.